1. Home
  2. SIBN vs EVMN Comparison

SIBN vs EVMN Comparison

Compare SIBN & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SI-BONE Inc.

SIBN

SI-BONE Inc.

HOLD

Current Price

$20.81

Market Cap

606.1M

Sector

Health Care

ML Signal

HOLD

EVMN

Evommune Inc.

N/A

Current Price

$17.15

Market Cap

628.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SIBN
EVMN
Founded
2008
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
606.1M
628.9M
IPO Year
2018
2025

Fundamental Metrics

Financial Performance
Metric
SIBN
EVMN
Price
$20.81
$17.15
Analyst Decision
Strong Buy
Buy
Analyst Count
7
5
Target Price
$25.57
$39.33
AVG Volume (30 Days)
563.7K
173.3K
Earning Date
11-10-2025
12-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$193,578,000.00
$13,000,000.00
Revenue This Year
$21.44
N/A
Revenue Next Year
$15.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
23.27
160.00
52 Week Low
$12.50
$13.89
52 Week High
$20.80
$24.03

Technical Indicators

Market Signals
Indicator
SIBN
EVMN
Relative Strength Index (RSI) 69.77 N/A
Support Level $18.34 N/A
Resistance Level $19.44 N/A
Average True Range (ATR) 0.72 0.00
MACD 0.05 0.00
Stochastic Oscillator 90.48 0.00

Price Performance

Historical Comparison
SIBN
EVMN

About SIBN SI-BONE Inc.

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

About EVMN Evommune Inc.

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Share on Social Networks: